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Introduction {#jdv15794-sec-0006}
============

Acne is estimated to affect 9.4% of the global population, making it the eighth most prevalent disease worldwide.[1](#jdv15794-bib-0001){ref-type="ref"} Although typically a disease of adolescence, it also affects a significant proportion of adults, including up to 22% of adult women.[2](#jdv15794-bib-0002){ref-type="ref"}, [3](#jdv15794-bib-0003){ref-type="ref"}, [4](#jdv15794-bib-0004){ref-type="ref"}, [5](#jdv15794-bib-0005){ref-type="ref"} It may persist for years with permanent consequences including scarring, low self‐esteem and embarrassment due to the visible nature of these marks.[6](#jdv15794-bib-0006){ref-type="ref"} Acne on the face is the most common, and often the most visible form of the disease and clinical studies has evaluated the efficacy of acne therapy on the face. However, back and chest acne have been estimated to occur in 61% and 45% of acne patients, respectively.[7](#jdv15794-bib-0007){ref-type="ref"} Until now, acne on the back has received only little attention in clinical studies.

Facial and truncal acne are considered pathophysiologically and clinically similar, with both locations presenting comparable types of lesions, although it may be possible to treat acne in both locations with similar therapeutic approaches.[8](#jdv15794-bib-0008){ref-type="ref"}, [9](#jdv15794-bib-0009){ref-type="ref"} Even though many topical and systemic treatments have been used in the past to treat acne, none has been specifically developed and clinically studied for the treatment of both facial and truncal acne.

Currently, topical retinoids are the mainstay of acne treatment, with adapalene, tretinoin and tazarotene available in various concentrations, formulations and combinations as well as orally administered isotretinoin. Retinoids have a central role in acne therapy because they inhibit the development of microcomedones, have anti‐inflammatory and immunomodulatory properties and reduce acne lesions.[10](#jdv15794-bib-0010){ref-type="ref"} Thus, they are considered a foundation of acne treatment. Retinoids can be combined with other topical therapies such as benzoyl peroxide or topical antibiotics, as well as systemic treatments including antibiotics and or oral contraceptives in more severe cases.[11](#jdv15794-bib-0011){ref-type="ref"}, [12](#jdv15794-bib-0012){ref-type="ref"}

Trifarotene cream 50 μg/g cream (hereafter trifarotene, developed by Nestlé Skin Health -- Galderma) has shown in acne strong anti‐comedogenic, antipigmenting activity and anti‐inflammatory properties *in vivo*.[13](#jdv15794-bib-0013){ref-type="ref"} This represents a new generation of retinoids, with a RAR‐γ selectivity that is highly expressed in the skin. It has a good *in vivo* metabolic stability in cultured keratinocytes and is rapidly metabolized in human liver microsomes, predicting an improved safety profile due to low systemic levels. In the Rhino mouse model, trifarotene showed a dose‐dependent comedolytic activity that is fully efficacious at a 10‐fold lower concentration than that for tazarotene 0.1% cream to achieve similar results.[13](#jdv15794-bib-0013){ref-type="ref"} No accumulation is expected with long‐term use.[13](#jdv15794-bib-0013){ref-type="ref"}, [14](#jdv15794-bib-0014){ref-type="ref"}

The primary objective of this study was to assess the long‐term safety of trifarotene for up to 52 weeks of treatment in patients with both moderate facial acne and truncal acne. Secondary objectives were the efficacy of trifarotene for up to 52 weeks and patient‐reported quality of life (QoL).

Patient selection and methods {#jdv15794-sec-0007}
=============================

This was a long‐term, multicentre, open‐label, non‐comparative, phase 3, safety and efficacy study in patients with moderate acne on the face and trunk. The study was conducted between February 2015 and February 2017.

The study complied with all local legal requirements for the conduct of a clinical study and was conducted in accordance with good clinical practices and the Principles of the Declaration of Helsinki. Prior to the inclusion of any patient, the study received local ethics committee or local independent review board approval. Patients provided written informed consent before participation. The study was registered in the US ClinicalTrials.gov register (Identifier n°: NCT02189629) and the European clinical trials register (EudraCT n°: 2014‐001755‐23).

In total, 453 patients were to be enrolled at 32 sites in Europe (18 sites) and the USA (14 sites). The study included patients 9 years of age or older at enrolment, with an Investigator Global Assessment (IGA, for face) score of 3 (moderate) on a 5‐point scale (from 0 = clear to 4 = severe), ≥20 inflammatory lesions and ≥25 non‐inflammatory lesions on the face, a physician\'s global assessment (PGA, for trunk) score of 3 (moderate) on a 5‐point scale (from 0 = clear to 4 = severe), and ≥20 inflammatory lesions and ≥20 non‐inflammatory lesions on the trunk (chest, shoulders, upper back, mid and lower back, if applicable). All investigators and study personnel were harmonized to the study‐specific measurements.

After the first application of trifarotene at study site, patients were instructed to apply for the first 12 weeks trifarotene at home once daily in the evening after washing and drying the skin. Patients were encouraged to use a non‐comedogenic and hypoallergenic moisturizer of their choice and were instructed not to apply moisturizer one hour before or one hour after study drug application. The investigator could reduce trifarotene application frequency, if tolerability issues arose. If, during the study, IGA and PGA met treatment success criteria, the protocol instructed: (i) If a patient\'s IGA = 0 and PGA = 0, treatment was discontinued; however, the patient had to continue to attend the scheduled study visits. (ii) If a patient\'s IGA = 0 and a PGA ≥ 1, treatment was discontinued on the face only. These patients were asked to continue to apply their treatment on the truncal region. (iii) If a patient\'s IGA was ≥1 and PGA = 0, treatment was discontinued on the truncal region, and the patient was instructed to continue to apply the treatment on the face.

Local tolerability signs and symptoms including erythema, scaling, dryness and stinging/burning were evaluated on a 4‐point scale \[0 (none) to 3 (severe) at Baseline and at Weeks 12, 20, 26, 38 and 52/ET\]. Assessments were conducted separately for the face and trunk. Treatment‐emergent adverse events (TEAE) were assessed through the study period. A TEAE was defined as an adverse event that occurred, or increased in severity, on or after the date of the first application of trifarotene. TEAEs were summarized per quarter (Q), based on the study day: 1 to 89 (Q1), 90 to 179 (Q2), 180 to 269 (Q3) and ≥270 (Q4).

Routine laboratory parameters (biochemistry, haematology and urinalysis) and pregnancy tests, when appropriate were monitored at defined time points during the study.

Efficacy parameters were assessed at Baseline and at Weeks 12, 20, 26, 38 and 52/ET. IGA was used to assess the face, and PGA was used to assess the reachable areas of the upper truncal region. For children aged 9--11 years who did not meet truncal acne inclusion criteria at the Screening and Baseline visits, PGA was performed at all planned scheduled visits. If, during the study, acne appeared on the trunk, treatment with trifarotene and tolerability assessments were begun at the investigator\'s discretion; these data were evaluated in the safety analysis.

Overall treatment success was defined at a particular study visit if a patient had an IGA or PGA score of '0' (clear) or '1' (almost clear) and at least a 2‐grade improvement from Baseline, depending of the anatomical area assessed.

Patients evaluated their facial acne improvement compared with their baseline disease status at Weeks 12, 26 and 52/ET, based on a 6‐point scale (from 0 = complete improvement to 5 = worse).

The dermatology life quality index (DLQI) and the children‐DLQI (C‐DLQI), for patients aged up to 16 years at Baseline, were completed by each patient at Baseline and Weeks 12, 26 and 52/ET.[15](#jdv15794-bib-0015){ref-type="ref"}, [16](#jdv15794-bib-0016){ref-type="ref"} The DLQI/C‐DLQI measured the dermatology‐related limitations of functional ability on patients' lives. The questionnaires were conducted prior to any acne assessment by the investigator, to avoid influencing the patient\'s answers. The higher the score (ranging from 0 to 30), the more the QOL was impaired.

For statistical analysis purposes, 'Baseline' evaluations were defined as the last measurements prior to the first application of trifarotene. No inferential statistical analysis was planned. All data were summarized descriptively using observed data. No imputation methods were used to impute the missing values.

For summary statistics, categorical variables were summarized by frequency and percentage for each response category. Continuous variables were summarized using means and standard deviations (mean ± SD). All local tolerability and efficacy endpoints, as well as DLQI/C‐DLQI, were summarized by visit.

SAS version 9.4 or above was used for all statistical analyses.

Results {#jdv15794-sec-0008}
=======

Study population {#jdv15794-sec-0009}
----------------

A total of 453 (99.6%) patients were enrolled and received trifarotene, and 348 (76.5%) completed the study. The most common reason for discontinuation was patient\'s request 53 (11.6%). A total of 376 (83%) patients completed at least 180 days, and 342 (75.5%) patients completed 360 days. Details about patient disposition are provided in Fig. [1](#jdv15794-fig-0001){ref-type="fig"}. The mean patient age was 18.3 ± 6.6 years, ranging from 9 to 54 years. Demographic and baseline characteristics for the PGA safety population were similar to the IGA safety population.

![Patient disposition. Screened patients were those who had signed the ICF. Enrolled patients were those who did not fail screening and were given trifarotene at Baseline visit. ^a^Of the 455 patients enrolled, 453 were treated (i.e. two patients did not apply study drug and returned the unused study drug).](JDV-34-166-g001){#jdv15794-fig-0001}

Detailed demographic and baseline characteristics are provided in Table [1](#jdv15794-tbl-0001){ref-type="table"}.

###### 

Demographic and baseline characteristics

                                                       Safety population (SAF, *N* = 453)   Safety PGA population (SAFT, *N* = 444)
  ---------------------------------------------------- ------------------------------------ -----------------------------------------
  **Age (years)**                                                                           
   Mean (SD)                                           18.3 ± 6.6                           18.4 ± 6.5
  **Age group,** ***n*** **(%)**                                                            
   \<18 years                                          286 (63.1)                           277 (62.4)
   ≥18 years                                           167 (36.9)                           167 (37.6)
   9--11 years                                         18 (4.0)                             9 (2.0)
  **Gender,** ***n*** **(%)**                                                               
   Male                                                227 (50.1)                           227 (51.1)
   Female                                              226 (49.9)                           217 (48.9)
  **Race,** ***n*** **(%)**                                                                 
   White                                               432 (95.4)                           424 (95.5)
   Black or African American                           12 (2.6)                             11 (2.5)
   Asian                                               3 (0.7)                              3 (0.7)
   American Indian or Alaska Native                    1 (0.2)                              1 (0.2)
   Native Hawaiian or Other Pacific Islander           3 (0.7)                              3 (0.7)
   Multiple                                            2 (0.4)                              2 (0.5)
   Other                                               0                                    0
  **Ethnicity,** ***n*** **(%)**                                                            
   Hispanic or Latino                                  47 (10.4)                            44 (9.9)
   Not Hispanic or Latino                              406 (89.6)                           400 (90.1)
  **Skin phototype,** ***n*** **(%)**                                                       
   Type I                                              13 (2.9)                             13 (2.9)
   Type II                                             188 (41.5)                           182 (41.0)
   Type III                                            184 (40.6)                           183 (41.2)
   Type IV                                             53 (11.7)                            52 (11.7)
   Type V                                              7 (1.5)                              7 (1.6)
   Type VI                                             2 (0.4)                              1 (0.2)
   Missing                                             6 (1.3)                              6 (1.4)
  **Baseline inflammatory facial lesion count**                                             
   *n*                                                 453                                  444
   Mean (SD)                                           15.0                                 15.2
  **Baseline non‐inflammatory facial lesion count**                                         
   *n*                                                 453                                  444
   Mean (SD)                                           58.2 ± 36.7                          58.5 ± 37.0
  **Baseline inflammatory truncal lesion count**                                            
   *n*                                                 446                                  444
   Missing                                             7                                    0
   Mean (SD)                                           43.4 ± 28.6                          43.5 ± 28.5
  **Baseline non‐inflammatory truncal lesion count**                                        
   Missing                                             7                                    0
   Mean (SD)                                           56.1 ± 39.5                          56.3 ± 39.4

Safety Population (SAF): All patients that were randomized and applied the study drug at least once. It includes all patients with facial acne/trunk acne and facial acne/without truncal acne.

Safety PGA Population (SAFT): All patients that were randomized and applied the study drug at least once on the trunk. It includes all patients with facial acne/truncal acne.

John Wiley & Sons, Ltd

Local tolerability and safety {#jdv15794-sec-0010}
-----------------------------

At Baseline, ˃80% of the patients did not exhibit any local tolerability signs/symptoms on the face and trunk. Table [2](#jdv15794-tbl-0002){ref-type="table"} provides percentages of patients reporting local tolerability signs/symptoms by severity observed with trifarotene on the face and trunk.

###### 

Local tolerability parameters worsened from Baseline (worst post‐baseline) on the face and trunk (SAFT Population)

  **Face (** ***N*** ** = 453)**   
  -------------------------------- ------------
  **Erythema**                     
   *n*                             449
   Mild, *n* (%)                   210 (46.8)
   Moderate, *n* (%)               111 (24.7)
   Severe, *n* (%)                 10 (2.2)
  **Scaling**                      
   *n*                             449
   Mild, *n* (%)                   210 (46.8)
   Moderate, *n* (%)               131 (29.2)
   Severe, *n* (%)                 10 (2.2)
  **Dryness**                      
   *n*                             449
   Mild, *n* (%)                   195 (43.4)
   Moderate, *n* (%)               140 (31.2)
   Severe, *n* (%)                 26 (5.8)
  **Stinging/Burning**             
   *n*                             449
   Mild, *n* (%)                   169 (37.6)
   Moderate, *n* (%)               95 (21.2)
   Severe, *n* (%)                 32 (7.1)

  **Trunk (** ***N*** ** = 446)**   
  --------------------------------- ------------
  **Erythema**                      
  * n*                              442
   Mild, *n* (%)                    131 (29.6)
   Moderate, *n* (%)                76 (17.2)
   Severe, *n* (%)                  24 (5.4)
  **Scaling**                       
   *n*                              442
   Mild, *n* (%)                    137 (31.0)
   Moderate, *n* (%)                48 (10.9)
   Severe, *n* (%)                  11 (2.5)
  **Dryness**                       
  * n*                              442
   Mild, *n* (%)                    152 (34.4)
   Moderate, *n* (%)                63 (14.3)
   Severe, *n* (%)                  12 (2.7)
  **Stinging/Burning**              
   *n*                              442
   Mild, *n* (%)                    111 (25.1)
   Moderate, *n* (%)                42 (9.5)
   Severe, *n* (%)                  21 (4.8)

Safety PGA Population (SAFT): All patients that were randomized and applied the study drug at least once on the trunk. It includes all patients with facial acne/truncal acne.

John Wiley & Sons, Ltd

The mean tolerability score, including worst score for each parameter during the study period, is presented in Fig. [2](#jdv15794-fig-0002){ref-type="fig"} for the face and in Fig. [3](#jdv15794-fig-0003){ref-type="fig"} for the trunk.

![Local tolerability by visit: mean scores of signs and symptoms on the face (SAF population). Safety Population (SAF): All patients that were randomized and applied the study drug at least once. It includes all patients with facial acne/trunk acne and facial acne/without truncal acne. Local tolerability parameters including erythema, scaling, dryness and stinging/burning were evaluated at each visit on a 4‐point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) at Baseline and at Weeks 12, 20, 26, 38 and 52/ET.](JDV-34-166-g002){#jdv15794-fig-0002}

![Local tolerability by visit: mean scores of signs and symptoms on the trunk (SAFT population). Safety PGA Population (SAFT): All patients that were randomized and applied the study drug at least once on the trunk. It includes all patients with facial acne/truncal acne. Local tolerability parameters including erythema, scaling, dryness and stinging/burning were evaluated at each visit on a 4‐point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) at Baseline and at Weeks 12, 20, 26, 38 and 52/ET.](JDV-34-166-g003){#jdv15794-fig-0003}

Overall, 468 TEAEs were reported in 218/453 (48.1%) patients during the whole study period, of which 57 (12.6%) patients had cutaneous AES related to trifarotene. Thirteen (2.9%) patients had AES related to trifarotene leading to discontinuation. The majority of all TEAEs that occurred during the first 3 months of the study. Serious TEAEs occurred in 10 (2.2%) of the patients; none were trifarotene‐related.

The most common cutaneous trifarotene‐related TEAEs were pruritus \[21 (4.6%) patients\], irritation \[19 (4.2%) patients\] and sunburn \[8 (1.8%) patients\]; these were mainly observed on treated areas and were of mild severity. Severe trifarotene‐related TEAEs occurred in 3 (0.7%) different patients: application site irritation, pruritus and erythema.

A total of 16 (3.5%) patients discontinued the study due to TEAEs, among which 13 (2.9%) discontinued due to related TEAEs. The latter were considered AESIs -- 10 events were skin irritation and three events were worsening of acne. All occurred on the face and trunk during the first 3 months were related and non‐serious. All patients discontinued from the study and followed up until complete resolution or stabilization.

Treatment‐emergent adverse events were also analysed among the subset of patients who extended the application of trifarotene to their middle and/or lower back and applied the cream at least once during the study period in that area. The safety profile in these patients (*n* = 231) was similar to that of the overall safety population.

No clinically meaningful change in routine laboratory parameter values was observed during the study.

Efficacy {#jdv15794-sec-0011}
--------

Both IGA and PGA success rates continuously improved over time, IGA success rates increased from 26.6% at Week 12 to 65.1% at Week 52; PGA success rates increased from 38.6% at Week 12 to 66.9% at Week 52. IGA and PGA success rates are given in Fig. [4](#jdv15794-fig-0004){ref-type="fig"}. Overall success (both IGA and PGA success in the same patient) was 57.9% at Week 52 (Fig. [5](#jdv15794-fig-0005){ref-type="fig"}).

![Evolution of the percent investigator\'s global assessment and physician global assessment success rates at baseline and weeks 12, 20, 26, 38 and 52 (SAFT population). Investigator\'s Global Assessment (IGA) and Physician Global Assessment (PGA) were scored on a 5‐point scale (from 0 = clear to 4 = severe).](JDV-34-166-g004){#jdv15794-fig-0004}

![Evolution of the overall percent investigator\'s global assessment and physician global assessment success in the same patient over 52 weeks (SAFT population). Overall treatment success was defined at a particular study visit if the same patient had an IGA/PGA score of "clear" or "almost clear" and at least a 2‐grade improvement from Baseline at any study visit.](JDV-34-166-g005){#jdv15794-fig-0005}

The percentage of patients who reported a marked or complete improvement of facial acne was 41.4% at Week 12, 54.8% at Week 26 and 66.6% at Week 52.

Figure [6](#jdv15794-fig-0006){ref-type="fig"} provides visual support of improvement of severity of acne on the face and trunk at different time points during the study.

![Acne severity of two patients at different time points. Patient n°1: Face, Acne severity on the face decreased from an IGA score of 3 to an IGA score of 1 at 12 weeks; Trunk, Acne severity on the trunk decreased from a PGA score of 3 to a PGA score of 2 at Week 12. Patient n°2: Face, Acne severity on the face decreased from an IGA score of 3 to an IGA score of 1 after 52 weeks.](JDV-34-166-g006){#jdv15794-fig-0006}

Quality of life {#jdv15794-sec-0012}
---------------

At Week 52 visit, 92/171 (53.8%) patients who had completed their assessments had scores from 0 to 1 (i.e. no effect of acne on their QOL) vs. 47/208 (22.6%) patients at Baseline visit (Table [3](#jdv15794-tbl-0003){ref-type="table"}).

###### 

Impact of acne on the patient\'s quality of life using the Dermatology Life Quality Index and the Children Dermatology Life Quality Index at Baseline and Week 52 (SAF Population)

                                     Baseline                    Week 52
  ---------------------------------- --------------------------- ---------------------------
  **DLQI**                           **(** ***N*** ** = 208)**   **(** ***N*** ** = 171)**
   No effect, *n* (%)                47 (22.6)                   92 (53.8)
   Small effect, *n* (%)             85 (40.9)                   61 (35.7)
   Moderate effect, *n* (%)          43 (20.7)                   14 (8.2)
   Very large effect, *n* (%)        33 (15.9)                   4 (2.3)
   Extremely large effect, *n* (%)   0                           0
  **C‐DLQI**                         **(** ***N*** ** = 246)**   **(** ***N*** ** = 177)**
   No effect, *n* (%)                76 (30.9)                   96 (54.2)
   Small effect, *n* (%)             115 (46.7)                  71 (40.1)
   Moderate effect, *n* (%)          49 (19.9)                   10 (5.6)
   Very large effect, *n* (%)        6 (2.4)                     0
   Extremely large effect, *n* (%)   0                           0

Safety Population (SAF): All patients that were randomized and applied the study drug at least once. It includes all patients with facial acne/trunk acne and facial acne/without truncal acne.

DLQI: Patients 17 years of age and older at Baseline visit; C‐DLQI: Patients aged ≤16 years at Baseline visit.

The meaning of the DLQI total scores was interpreted as follows: no effect (0--1), small effect (2--6), moderate effect (7--12), very large effect (13--18) or extremely large effect (19--30).

John Wiley & Sons, Ltd

Discussion and conclusions {#jdv15794-sec-0013}
==========================

This 52‐week long‐term study assessed for the first time the safety and efficacy of the first‐in‐class selective RAR‐γ agonist trifarotene. Moreover, this study is the first to systematically evaluate a treatment for both moderate facial acne and truncal acne in a prospective long‐term tolerability, safety and efficacy study.

A total of 348 (76.5%) patients completed the study; a high completion rate for a 52‐week study, especially when considering the age of the population (more than 63% of the patients were younger than 18 years of age). Relatively few patients aged between 9 and 11 years were enrolled. This was due the low prevalence with truncal acne found in this group.

During this study, 103 trifarotene‐related TEAEs were reported in 57 (12.6%) of the patients. Only 16 (3.5%) of these TEAEs led to study discontinuation, with a majority (2.9%) occurring during the first quarter after treatment initiation. The most common cutaneous TEAEs related to trifarotene were application site pruritus \[in 21 (4.6%) of the patients\], application site irritation \[in 19 (4.2%) of the patients\] and sunburn \[in 8 (1.8%) of the patients\]; all were observed on treated areas. As observed with other retinoids, the majority of these local adverse events occurred during the first weeks of treatment, subsiding thereafter; all were mild or moderate in intensity.[17](#jdv15794-bib-0017){ref-type="ref"}, [18](#jdv15794-bib-0018){ref-type="ref"}, [19](#jdv15794-bib-0019){ref-type="ref"} Local tolerability on the trunk was better than on the face. A possible explanation could be that the epidermis of the back is thicker than of the face. Facial and truncal skin are exposed to different environmental challenges. Facial skin is more frequently exposed to environmental sources of irritation and damage, and often remains unprotected against external triggers such as UV light, temperature and pollution, while the skin on the trunk is more frequently exposed to heat, moisture and occlusion.[9](#jdv15794-bib-0009){ref-type="ref"} The concomitant use of moisturizer facilitated management of 'retinoid dermatitis' as reported recently.[20](#jdv15794-bib-0020){ref-type="ref"} To limit retinoid‐related side‐effects, short contact therapy (SCT) was proposed for topical treatments with retinoids.[21](#jdv15794-bib-0021){ref-type="ref"} To address this issue, SCT study was performed during the development programme of trifarotene. Results from this pilot study showed a better tolerability but reduced efficacy of trifarotene (unpublished results).

Overall success (IGA and PGA success in the same subject) increased continuously with a greater acne improvement on the trunk than on the face. At 52 weeks of treatment, 57.9% of the patients experienced overall success, a significant therapeutic benefit. The continued improvement, reaching high rates of overall success (face and trunk clear or almost clear in the same subject) over 52 weeks, is important for healthcare providers to motivate and encourage patients to follow long‐term topical therapy with the expectation of further benefits.

The QOL of adults and children substantially improved over the study period and was positively impacted by the improved acne severity.

Patients had a high treatment compliance of 95.3% for both face and trunk. The treatment regimen and manageable safety profile might have played a role in the observed treatment compliance, an observation reported by previous investigations.[22](#jdv15794-bib-0022){ref-type="ref"}

The open‐label and non‐comparative design of this study has certain inherent limitations and biases. Nevertheless, the design of this study was appropriate for the intended objectives, with evaluation of local tolerance and safety of trifarotene in patients with acne on both the face and trunk being the primary aim. The results obtained during the study confirmed the primary study objectives demonstrating that trifarotene is safe and well tolerated. One yet unpublished phase 2 12‐week study in patients with moderate to severe acne evaluated three increasing therapeutic concentrations of trifarotene cream (25, 50 and 100 μg/g) vs. vehicle and tazarotene 0.1% gel. The dose strength of trifarotene 50 μg/g was shown to be more effective than the lower concentration (trifarotene 25 μg/g) and with regard to the higher concentration (trifarotene 100 μg/g) in 2‐point reduction of Investigator\'s Global Assessment (IGA) scores and per cent decrease in inflammatory lesion count but less effective in reduction of total lesion count than trifarotene 100 μg/g cream. Although both doses of 50 and 100 μg/g of trifarotene provided a positive benefit/risk ratio in the treatment of acne vulgaris when compared to vehicle, the superior safety and local tolerability profile of trifarotene 50 μg/g cream over trifarotene 100 μg/g and tazarotene 0.1% gel argued in favour of carrying this dose forward in phase 3. Two vehicle well‐controlled, identical phase 3 studies in the target population further substantiated the clinical benefit of trifarotene 50 μg/g cream of both facial and truncal acne.[23](#jdv15794-bib-0023){ref-type="ref"}

In conclusion, in this 52‐week study, once‐daily application of trifarotene 50 μg/g cream was safe, well tolerated and effective in patients with moderate facial and truncal acne, providing continuous improvement over time to patients. The present results also support the acceptable safety profile of trifarotene. Moreover, this is the first comprehensive long‐term study of truncal acne using a validated methodology. Thus, this study design could serve as a model for future investigations of this largely ignored clinical condition.

The authors would like to thank the Trifarotene LTS study teams in Sophia Antipolis, France and Fort Worth -- Texas, USA; all investigators and research staff in Europe and the United States who participated in this clinical trial and acknowledge the writing support of Karl Patrick Göritz, SMWS -- Scientific and Medical Writing Services, France.
